Novo Nordisk sees strong first-half sales growth

4 August 2022

Reporting financial results for the first half of 2022 late yesterday, Danish diabetes care giant Novo Nordisk (NOV: N) said that sales increased by 25% in Danish kroner and by 16% at constant exchange rates to 83.3 billion kroner ($11.4 billion) in the six months.

Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to 37.5 billion kroner. Novo Nordisk reported second-quarter operating profit of 18.4 billion kroner, just above the 18.3 billion forecast by analysts, according to Refinitiv data. However, the New York traded shares of the company closed down 12.7% at $99.91.

Sales in International Operations increased by 15% in Danish kroner (10% at CER), and sales in North America Operations increased by 36% in Danish kroner (24% at CER).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK